Skip to main content

Advertisement

Fig. 5 | Breast Cancer Research

Fig. 5

From: Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Fig. 5

Anti-human epidermal growth factor receptor 2 (anti-HER2) T-helper type-1 (Th1) deficit in patients without pathologic complete response (non-pCR) is not attributable to lack of immune competence, host-level T cell anergy, or increase in immunosuppressive phenotypes. Peripheral blood mononuclear cells (PBMC) from pCR and non-pCR patients did not differ significantly in (a) immune competence – measured by IFN-γ production to anti-CD3/anti-CD28 stimulus or recall stimuli tetanus toxoid and Candida albicans – by enzyme-linked immunosorbent spot. Results presented as median ± IQR interferon-γ (IFN-γ) spot-forming cells (SFC)/2 × 105 cells. b, c Relative proportions of CD3+CD4+ (b, top) or CD3+CD8+ T-cells (b, bottom), Treg (CD4+CD25+FoxP3+) (c, top) or myeloid-derived suppressor cells (MDSC) (CD11b+CD33+HLA-DRCD83) (c, bottom) by flow cytometry. Representative stains within groups are shown; results in histograms are expressed as mean proportions (%) ± standard error of the mean as indicated

Back to article page